Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
laropiprant + montelukast
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Laropiprant + montelukast is a combination of two small molecule drugs investigated for the treatment of asthma and seasonal allergic rhinitis. Laropiprant is a selective antagonist of the prostaglandin D2 receptor subtype DP1, which blocks the action of prostaglandin D2, a mediator involved in inflammation and vasodilation. Montelukast is an antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), inhibiting leukotriene-mediated bronchoconstriction and inflammation. The combination was studied to assess whether dual inhibition could provide additional benefit in respiratory diseases characterized by allergic inflammation. Clinical studies did not demonstrate significant efficacy for laropiprant alone or in combination with montelukast compared to standard treatments or placebo in asthma or allergic rhinitis[1].
- Brand names
- singulair
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)PTGDR (Prostanoid DP1 receptor)
Beyond the preview
Go deeper on laropiprant + montelukast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on laropiprant + montelukast.